Atezolizumab plus bevacizumab versus sorafenib as first-line treatment for unresectable hepatocellular carcinoma: a cost-effectiveness analysis

Cancer Communications

article

Yanli Hou¹  Bin Wu² 

[1] Department of Radiation Oncology, Ren Ji Hospital, School of Medicine, Shanghai Jiaotong University;Medical Decision and Economic Group, Department of Pharmacy, Ren Ji Hospital, South Campus, School of Medicine, Shanghai Jiaotong University

关键词: Hepatocellular carcinoma;    Atezolizumab;    Bevacizumab;    Sorafenib;    Cost-effectiveness;   

DOI  :  10.1002/cac2.12110

学科分类：社会科学、人文和艺术（综合）

来源: Springer

【 摘 要 】

Liver cancer is the third leading cause of cancer deaths worldwide and accounted for 8.9% of all neoplasms, as shown by the Global Burden of Disease Study 2017 [1]. Hepatocellular carcinoma (HCC) comprises 75%-85% of liver cancers [2]. The abysmal statistic is partly contributed by the fact that only 30%-40% of all patients are diagnosed at early stages that are amenable to potentially curative treatments [3]. For over a decade, the availability of new agents, such as lenvatinib- and sorafenib-based targeted therapy, has significantly improved the outcome of patients with advanced HCC, prolonging the median overall survival (OS) from 4-8 months to 10-15 months [4, 5]. However, the therapeutic options for advanced HCC are still limited, and the prognosis is poor.

【 授权许可】

CC BY|CC BY-NC-ND